LAB Stock Summary and Trading Ideas (Standard Biotools | NASDAQ:LAB)

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Standard Biotools trades on the NASDAQ stock market under the symbol LAB.

As of January 27, 2026, LAB stock price declined to $1.50 with 108,549 million shares trading.

LAB has a beta of 1.27, meaning it tends to be more sensitive to market movements. LAB has a correlation of 0.12 to the broad based SPY ETF.

LAB has a market cap of $576.85 million. This is considered a Small Cap stock.

Last quarter Standard Biotools reported $20 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.05.

In the last 3 years, LAB traded as high as $3.16 and as low as $.92.

The top ETF exchange traded funds that LAB belongs to (by Net Assets): IWM, VTI, ARKG, VXF, IBB.

LAB has underperformed the market in the last year with a price return of -9.1% while the SPY ETF gained +15.7%. However, in the short term, LAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.6% vs +3.1% return in SPY. But in the last 2 weeks, LAB shares have been beat by the market, returning -0.7% compared to an SPY return of +0.1%.

LAB support price is $1.46 and resistance is $1.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LAB shares will trade within this expected range on the day.